-- Roche’s Perjeta for Breast Cancer Wins Approval
-- B y   A n n a   E d n e y
-- 2012-06-11T16:42:28Z
-- http://www.bloomberg.com/news/2012-06-09/roche-s-prejeta-for-breast-cancer-wins-u-s-fda-approval.html
(Corrects drug spelling in headline, second paragraph of
story published June 8.)  Roche Holding AG (ROG) ’s personalized drug
treatment for a fast-growing type of  breast cancer  won approval
from U.S. regulators.  Perjeta, chemically known as pertuzumab, is designed to
work with the Basel, Switzerland-based company’s Herceptin and
chemotherapy to attack breast cancer that has spread in patients
who have a certain gene mutation. The  Food and Drug
Administration  today cleared Perjeta for consumer use, Roche’s
Genentech unit said in a statement.  To contact the reporter on this story:
Anna Edney in Washington at 
 aedney@bloomberg.net .  To contact the editor responsible for this story:
Reg Gale at 
 rgale5@bloomberg.net  